KDU731, an orally active C. parvum PI4K inhibitor with an IC 50 value of 25 nM, blocks Cryptosporidium infection in vitro and in vivo. KDU731 is a promising agent candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety .
In Vivo
KDU731 (orally administration; 7 or 10mg/kg; 16 days) has potent activity against Cryptosporidium in immunocompromised IFN-γ KO mice and dramatically reduces oocyst shedding. KDU731 (orally administration; 5 mg/kg; every 12 hours for 7 days) is tolerated in all calves, and treated calves shed significantly fewer oocysts than vehicle treated calves in their stool. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6-8 week old C57BL/6 IFN-γ-knockout mice with 10,000 oocysts Dosage: 7 or 10 mg/kg Administration: Orally administration; 7 or 10 mg/kg; 16 days Result: Resulted in significant reduction of oocyst shedding. Animal Model: Neonatal calves with 5 x 10 7 oocysts Dosage: 5 mg/kg Administration: Orally administration; 5 mg/kg; every 12 hours for 7 days Result: Resulted in significant reduction of oocyst shedding in treated calves in their stool.
